Trial of MS1819, Pancreatic Enzyme Therapy, May Add New Patient Arm
AzurRx BioPharma is requesting a new patient arm be added to its ongoing Phase 2b trial investigating MS1819 capsules as a treatment for exocrine pancreatic insufficiency (EPI) in people with cystic fibrosis (CF). The request, filed with the U.S. Food and Drug Administration (FDA), would add a patient group…